165 related articles for article (PubMed ID: 16298159)
1. Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein.
Lie J; Lankhuizen IM; Gross B; van Gent T; van Haperen R; Scheek L; Staels B; de Crom R; van Tol A
Biochim Biophys Acta; 2005 Dec; 1738(1-3):48-53. PubMed ID: 16298159
[TBL] [Abstract][Full Text] [Related]
2. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate.
Bouly M; Masson D; Gross B; Jiang XC; Fievet C; Castro G; Tall AR; Fruchart JC; Staels B; Lagrost L; Luc G
J Biol Chem; 2001 Jul; 276(28):25841-7. PubMed ID: 11342537
[TBL] [Abstract][Full Text] [Related]
3. Inducible expression of phospholipid transfer protein (PLTP) in transgenic mice: acute effects of PLTP on lipoprotein metabolism.
Moerland M; Anghelescu N; Samyn H; van Haperen R; van Gent T; Strouboulis J; van Tol A; Grosveld F; de Crom R
Transgenic Res; 2007 Aug; 16(4):503-13. PubMed ID: 17437182
[TBL] [Abstract][Full Text] [Related]
4. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes.
Jiang X; Francone OL; Bruce C; Milne R; Mar J; Walsh A; Breslow JL; Tall AR
J Clin Invest; 1996 Nov; 98(10):2373-80. PubMed ID: 8941656
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in atherosclerosis in mice with elevated phospholipid transfer protein activity are related to decreased plasma high density lipoproteins and not to increased production of triglycerides.
Lie J; Moerland M; van Gent T; van Haperen R; Scheek L; Sadeghi-Niaraki F; de Crom R; van Tol A
Biochim Biophys Acta; 2006 Sep; 1761(9):1070-7. PubMed ID: 16935026
[TBL] [Abstract][Full Text] [Related]
6. Novel roles of hepatic lipase and phospholipid transfer protein in VLDL as well as HDL metabolism.
van Haperen R; Samyn H; van Gent T; Zonneveld AJ; Moerland M; Grosveld F; Jansen H; Dallinga-Thie GM; van Tol A; de Crom R
Biochim Biophys Acta; 2009 Oct; 1791(10):1031-6. PubMed ID: 19524061
[TBL] [Abstract][Full Text] [Related]
7. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels.
Jiang XC; Bruce C; Mar J; Lin M; Ji Y; Francone OL; Tall AR
J Clin Invest; 1999 Mar; 103(6):907-14. PubMed ID: 10079112
[TBL] [Abstract][Full Text] [Related]
8. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice.
Samyn H; Moerland M; van Gent T; van Haperen R; Grosveld F; van Tol A; de Crom R
Atherosclerosis; 2009 Jun; 204(2):429-34. PubMed ID: 19100548
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo.
Rotllan N; Llaverías G; Julve J; Jauhiainen M; Calpe-Berdiel L; Hernández C; Simó R; Blanco-Vaca F; Escolà-Gil JC
Biochim Biophys Acta; 2011 Feb; 1811(2):104-10. PubMed ID: 21126601
[TBL] [Abstract][Full Text] [Related]
10. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.
Berthou L; Duverger N; Emmanuel F; Langouët S; Auwerx J; Guillouzo A; Fruchart JC; Rubin E; Denèfle P; Staels B; Branellec D
J Clin Invest; 1996 Jun; 97(11):2408-16. PubMed ID: 8647932
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.
van der Hoogt CC; de Haan W; Westerterp M; Hoekstra M; Dallinga-Thie GM; Romijn JA; Princen HM; Jukema JW; Havekes LM; Rensen PC
J Lipid Res; 2007 Aug; 48(8):1763-71. PubMed ID: 17525476
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of PLTP is atherogenic in apolipoprotein E deficient mice.
van Haperen R; van Gent T; van Tol A; de Crom R
Atherosclerosis; 2013 Mar; 227(1):37-42. PubMed ID: 23313246
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol.
Post SM; Groenendijk M; van der Hoogt CC; Fievet C; Luc G; Hoekstra M; Princen HM; Staels B; Rensen PC
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2724-30. PubMed ID: 17008588
[TBL] [Abstract][Full Text] [Related]
15. Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein.
Post SM; de Crom R; van Haperen R; van Tol A; Princen HM
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):892-7. PubMed ID: 12649089
[TBL] [Abstract][Full Text] [Related]
16. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein.
Dallinga-Thie GM; van Tol A; Dullaart RP;
Biochim Biophys Acta; 2009 Aug; 1791(8):714-8. PubMed ID: 19303940
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI-CIII-AIV transgenic mice.
Srivastava RA; He S; Newton RS
Biochim Biophys Acta; 2011 Feb; 1811(2):76-83. PubMed ID: 21081177
[TBL] [Abstract][Full Text] [Related]
18. Altered hepatic lipid status and apolipoprotein A-I metabolism in mice lacking phospholipid transfer protein.
Siggins S; Bykov I; Hermansson M; Somerharju P; Lindros K; Miettinen TA; Jauhiainen M; Olkkonen VM; Ehnholm C
Atherosclerosis; 2007 Jan; 190(1):114-23. PubMed ID: 16554055
[TBL] [Abstract][Full Text] [Related]
19. Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport.
Kuwano T; Bi X; Cipollari E; Yasuda T; Lagor WR; Szapary HJ; Tohyama J; Millar JS; Billheimer JT; Lyssenko NN; Rader DJ
J Lipid Res; 2017 Apr; 58(4):731-741. PubMed ID: 28137768
[TBL] [Abstract][Full Text] [Related]
20. Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study.
Samyn H; Moerland M; van Gent T; van Haperen R; Metso J; Grosveld F; Jauhiainen M; van Tol A; de Crom R
J Lipid Res; 2008 Dec; 49(12):2504-12. PubMed ID: 18711210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
